meglumine

Summary

Summary: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.

Top Publications

  1. Neves L, Talhari A, Gadelha E, Silva Junior R, Guerra J, Ferreira L, et al. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. An Bras Dermatol. 2011;86:1092-101 pubmed
    ..Moreover, treatment outcome may depend on the causative species of Leishmania...
  2. Hailu W, Weldegebreal T, Hurissa Z, Tafes H, Omollo R, Yifru S, et al. Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection. Trans R Soc Trop Med Hyg. 2010;104:706-12 pubmed publisher
    ..sodium antimony gluconate) or generic sodium stibogluconate (SSG), except in Uganda where Glucantime(®) (meglumine antimoniate) has been in use for at least a decade...
  3. Miró G, Gálvez R, Fraile C, Descalzo M, Molina R. Infectivity to Phlebotomus perniciosus of dogs naturally parasitized with Leishmania infantum after different treatments. Parasit Vectors. 2011;4:52 pubmed publisher
    ..Thirty two dogs with clinical leishmaniosis were assigned to one of three treatment groups: meglumine antimoniate plus allopurinol (Group A), meglumine antimoniate (Group B) or allopurinol (Group C)...
  4. Kinner S, Maderwald S, Parohl N, Albert J, Corot C, Robert P, et al. Contrast-enhanced magnetic resonance angiography in rabbits: evaluation of the gadolinium-based agent p846 and the iron-based blood pool agent p904 in comparison with gadoterate meglumine. Invest Radiol. 2011;46:524-9 pubmed publisher
    ..as well as an ultra-small particle of iron oxide agent (P904) in contrast-enhanced magnetic resonance angiography (MRA) in rabbits and to compare those agents with gadoterate meglumine (Gd-DOTA) for first pass and steady state imaging.
  5. Almeida O, Santos J. Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review. An Bras Dermatol. 2011;86:497-506 pubmed
    ..Pentavalent antimonial compounds have been the drugs of choice for treatment of this disease for over 50 years. Despite their effectiveness, these drugs require daily injections, have many side effects and present prolonged healing time...
  6. Goodwin M, Dobson J, Sirlin C, Lim B, Stella D. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics. 2011;31:1547-68 pubmed publisher
  7. Kawel N, Nacif M, Zavodni A, Jones J, Liu S, Sibley C, et al. T1 mapping of the myocardium: intra-individual assessment of the effect of field strength, cardiac cycle and variation by myocardial region. J Cardiovasc Magn Reson. 2012;14:27 pubmed publisher
    ..The purpose of this study was to evaluate acquisition factors that may result in variation of measured T1 time and ECV including magnetic field strength, cardiac phase and myocardial region...
  8. Khatami A, Talaee R, Rahshenas M, Khamesipour A, Mehryan P, Tehrani S, et al. Dressings combined with injection of meglumine antimoniate in the treatment of cutaneous leishmaniasis: a randomized controlled clinical trial. PLoS ONE. 2013;8:e66123 pubmed publisher
    ..Despite some reasonable explanation for their potential benefits, there is only trace evidence regarding the role of dressings in the treatment of CL...
  9. Vasconcellos E, Pimentel M, Schubach A, de Oliveira R, Azeredo Coutinho R, Silva F, et al. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006). Am J Trop Med Hyg. 2012;87:257-60 pubmed
    We evaluated the effectiveness and safety of intralesional meglumine antimoniate (MA) in 24 not submitted to previous treatment patients with cutaneous leishmaniasis (CL) and with contraindication to systemic therapy...

Scientific Experts

More Information

Publications62

  1. Hajjaran H, Azarian B, Mohebali M, Hadighi R, Assareh A, Vaziri B. Comparative proteomics study on meglumine antimoniate sensitive and resistant Leishmania tropica isolated from Iranian anthroponotic cutaneous leishmaniasis patients. East Mediterr Health J. 2012;18:165-71 pubmed
    In order to define the protein expressional changes related to the process of meglumine antimoniate resistance in anthroponotic cutaneous leishmaniasis (CL), we performed a comparative proteomics analysis on sensitive and resistant ..
  2. Sado D, Flett A, Banypersad S, White S, Maestrini V, Quarta G, et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart. 2012;98:1436-41 pubmed publisher
  3. Kawel N, Nacif M, Santini F, Liu S, Bremerich J, Arai A, et al. Partition coefficients for gadolinium chelates in the normal myocardium: comparison of gadopentetate dimeglumine and gadobenate dimeglumine. J Magn Reson Imaging. 2012;36:733-7 pubmed publisher
  4. Pierantozzi M, Roura X, Paltrinieri S, Poggi M, Zatelli A. Variation of proteinuria in dogs with leishmaniasis treated with meglumine antimoniate and allopurinol: a retrospective study. J Am Anim Hosp Assoc. 2013;49:231-6 pubmed publisher
    ..degree of proteinuria, evaluated by the urine protein/creatinine ratio (UP/C), changes following treatment with meglumine antimoniate and allopurinol...
  5. Pimentel M, Baptista C, Rubin E, Vasconcellos E, Lyra M, Salgueiro M, et al. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report. Rev Soc Bras Med Trop. 2011;44:254-6 pubmed
    ..The lesion relapsed following two systemic treatments with meglumine antimoniate. The patient was treated with amphotericin B, which was interrupted due to poor tolerance...
  6. Borborema S, Schwendener R, Osso J, de Andrade H, do Nascimento N. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages. Int J Antimicrob Agents. 2011;38:341-7 pubmed publisher
    ..The aim of this study was to develop novel meglumine antimoniate (MA)-containing liposome formulations and to analyse their antileishmanial activity and uptake by ..
  7. Shokri A, Sharifi I, Khamesipour A, Nakhaee N, Fasihi Harandi M, Nosratabadi J, et al. The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate. Parasitol Res. 2012;110:1113-7 pubmed publisher
    ..effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate (MA, Glucantime) was evaluated using colorimetric assay (MTT) and in a macrophage model, ..
  8. Wagner M, Schilling R, Doeblin P, Huppertz A, Luhur R, Schwenke C, et al. Macrocyclic contrast agents for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison of gadobutrol and gadoterate meglumine. Eur Radiol. 2013;23:108-14 pubmed publisher
    To compare 0.15 mmol/kg gadobutrol for late gadolinium enhancement (LGE) imaging of chronic myocardial infarction with a relaxivity-adjusted dose of gadoterate meglumine (Gd-DOTA).
  9. Kashani M, Sadr B, Nilforoushzadeh M, Arasteh M, Babakoohi S, Firooz A. Treatment of acute cutaneous leishmaniasis with intralesional injection of meglumine antimoniate: comparison of conventional technique with mesotherapy gun. Int J Dermatol. 2010;49:1034-7 pubmed publisher
    The gold standard treatment of Old World leishmaniasis, a common tropical parasitic infestation, is intralesional meglumine antimoniate injection...
  10. Ishiguchi T, Takahashi S. Safety of gadoterate meglumine (Gd-DOTA) as a contrast agent for magnetic resonance imaging: results of a post-marketing surveillance study in Japan. Drugs R D. 2010;10:133-45 pubmed publisher
    ..If precautions could be taken before the repeated administration of gadolinium-based contrast media, then the awareness and management of adverse reactions would be more efficient...
  11. Layegh P, Rahsepar S, Rahsepar A. Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults. Am J Trop Med Hyg. 2011;84:539-42 pubmed publisher
    ..They received meglumine antimoniate; 20 mg/kg/day for 20 days, their improvement rate was evaluated 20 and 45 days after treatment...
  12. Cordoba S, Gandolfo Cano M, Aguado M, Huerta Brogera M, Romero A, Martínez Morán C, et al. Delayed allergic skin reactions due to intralesional meglumine antimoniate therapy for cutaneous leishmaniasis. Allergy. 2012;67:1609-11 pubmed publisher
    ..The pentavalent antimonials are considered the first-choice drugs for treatment of leishmaniasis. Intralesional therapy is used to minimize the systemic effects of the drug...
  13. Anzalone N, Scarabino T, Venturi C, Cristaudo C, Tartaro A, Scotti G, et al. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting. Eur J Radiol. 2013;82:139-45 pubmed publisher
    Two macrocyclic extracellular contrast agents, one-molar neutral gadobutrol and ionic gadoterate meglumine, were compared to determine the overall preference for one or the other in a clinical setting.
  14. Rubiano L, Miranda M, Muvdi Arenas S, Montero L, Rodriguez Barraquer I, Garcerant D, et al. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis. 2012;205:684-92 pubmed publisher
    ..Children have a lower response rate to antimonial drugs and higher elimination rate of antimony (Sb) than adults. Oral miltefosine has not been evaluated for pediatric cutaneous leishmaniasis...
  15. Ait Oudhia K, Gazanion E, Sereno D, Oury B, Dedet J, Pratlong F, et al. In vitro susceptibility to antimonials and amphotericin B of Leishmania infantum strains isolated from dogs in a region lacking drug selection pressure. Vet Parasitol. 2012;187:386-93 pubmed publisher
    ..Moreover, our data showed that isolates belonging to the relatively rare zymodeme of L. infantum, MON-281, were less susceptible to antimony than MON-1, when at the same time there was no significant difference for amphotericin B...
  16. Cao X, Deng W, Fu M, Wang L, Tong S, Wei Y, et al. In vitro release and in vitro-in vivo correlation for silybin meglumine incorporated into hollow-type mesoporous silica nanoparticles. Int J Nanomedicine. 2012;7:753-62 pubmed publisher
    ..The purpose of this study was to develop a sustained drug-release model for water-soluble drugs using silica nanoparticles...
  17. da Silva S, Amorim I, Ribeiro R, Azevedo E, Demicheli C, Melo M, et al. Efficacy of combined therapy with liposome-encapsulated meglumine antimoniate and allopurinol in treatment of canine visceral leishmaniasis. Antimicrob Agents Chemother. 2012;56:2858-67 pubmed publisher
    An innovative liposomal formulation of meglumine antimoniate (LMA) was recently reported to promote both long-term parasite suppression and reduction of infectivity to sand flies in dogs with visceral leishmaniasis...
  18. Esfandiarpour I, Farajzadeh S, Rahnama Z, Fathabadi E, Heshmatkhah A. Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis. Int J Dermatol. 2012;51:1221-5 pubmed publisher
    ..This study aimed to evaluate the adverse effects of intralesional injection of meglumine antimoniate (Glucantime(®) ) and its influence on clinical laboratory parameters.
  19. Friedrich K, Vieira F, Porrozzi R, Marchevsky R, Miekeley N, Grimaldi G, et al. Disposition of antimony in rhesus monkeys infected with Leishmania braziliensis and treated with meglumine antimoniate. J Toxicol Environ Health A. 2012;75:63-75 pubmed publisher
    ..braziliensis-infected monkeys (Macaca mulatta) treated with a 21-d course of low (LOW) or standard (STD) meglumine antimoniate (MA) dosage regimens (5 or 20 mg Sb(V)/kg body weight/d im)...
  20. Flett A, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging. 2011;4:150-6 pubmed publisher
  21. Kawel N, Nacif M, Zavodni A, Jones J, Liu S, Sibley C, et al. T1 mapping of the myocardium: intra-individual assessment of post-contrast T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and Gd-BOPTA. J Cardiovasc Magn Reson. 2012;14:26 pubmed publisher
    ..The purpose of this study was to perform an intra-individual assessment of normal T1 time and ECV for two different contrast agents...
  22. Noli C, Auxilia S. Treatment of canine Old World visceral leishmaniasis: a systematic review. Vet Dermatol. 2005;16:213-32 pubmed
    ..The evaluation of clinical trials provided good evidence for recommending the use of meglumine antimoniate at a minimum dosage of 100 mg kg(-1) daily for at least 3-4 weeks, combined with allopurinol in ..
  23. Shamsi Meymandi S, Zandi S, Aghaie H, Heshmatkhah A. Efficacy of CO(2) laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate. J Eur Acad Dermatol Venereol. 2011;25:587-91 pubmed publisher
    ..Several types of treatments have been suggested, but none of them is completely effective and without side-effects. CO(2) laser has a specific thermolysis effect on infected tissues in CL...
  24. Grazioli L, Morana G, Kirchin M, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology. 2005;236:166-77 pubmed
    ..To prospectively determine the accuracy of differentiating benign focal nodular hyperplasia (FNH) from hepatic adenoma (HA) and liver adenomatosis (LA) by using gadobenate dimeglumine-enhanced magnetic resonance (MR) imaging...
  25. Miró G, Oliva G, Cruz I, Cañavate C, Mortarino M, Vischer C, et al. Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. Vet Dermatol. 2009;20:397-404 pubmed publisher
    ..the current reference combination therapy, meglumine antimoniate-allopurinol, for canine leishmaniosis...
  26. Cruz A, Rainey P, Herwaldt B, Stagni G, Palacios R, Trujillo R, et al. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis. 2007;195:602-8 pubmed
    ..In some settings, the response to pentavalent antimonial therapy for leishmaniasis may be lower in children than in adults. We hypothesized that there are age-dependent pharmacokinetic differences of potential clinical relevance...
  27. Hadighi R, Boucher P, Khamesipour A, Meamar A, Roy G, Ouellette M, et al. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res. 2007;101:1319-22 pubmed
    ..However, these resistant isolates were shown to be sensitive to miltefosine and paromomycin. The latter two drugs could thus be useful alternatives for the treatment of leishmaniasis in Iran even for SbV-resistant isolates...
  28. Torres M, Bardagi M, Roura X, Zanna G, Ravera I, Ferrer L. Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol. Vet J. 2011;188:346-51 pubmed publisher
    Twenty-three dogs with a diagnosis of leishmaniosis (clinical stage II) were treated with meglumine antimoniate and allopurinol and were followed up for 2-9 years...
  29. Rodrigues A, Hueb M, Santos T, Fontes C. [Factors associated with treatment failure of cutaneous leishmaniasis with meglumine antimoniate]. Rev Soc Bras Med Trop. 2006;39:139-45 pubmed
    We investigated factors associated with treatment failure in the treatment of cutaneous leishmaniasis with meglumine antimony in a reference service in Mato Grosso State...
  30. Firooz A, Khamesipour A, Ghoorchi M, Nassiri Kashani M, Eskandari S, Khatami A, et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol. 2006;142:1575-9 pubmed
    To determine the efficacy and safety of imiquimod in combination with meglumine antimoniate in treating cutaneous leishmaniasis.
  31. Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop. 2007;103:33-40 pubmed
    ..oral drug for the treatment of zoonotic cutaneous leishmaniasis caused by Leishmania major in comparison with meglumine antimoniate. Complete clinical response was defined as 100% re-epithelialization of the lesion...
  32. Zauli Nascimento R, Miguel D, Yokoyama Yasunaka J, Pereira L, Pelli de Oliveira M, Ribeiro Dias F, et al. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B. Trop Med Int Health. 2010;15:68-76 pubmed publisher
    ..Our susceptibility assays to meglumine antimoniate were performed against intracellular amastigotes after standardizing an in vitro model of macrophage ..
  33. Gupta P, Bansal A. Spray drying for generation of a ternary amorphous system of celecoxib, PVP, and meglumine. Pharm Dev Technol. 2005;10:273-81 pubmed
    ..Coprocessing of celecoxib (CEL), poly(vinyl pyrrolidone), and meglumine by spray drying resulted in an amorphous drug product that provided enhanced solubility and stability to an ..
  34. Morais Teixeira E, Carvalho A, Costa J, Duarte S, Mendonça J, Boechat N, et al. In vitro and in vivo activity of meglumine antimoniate produced at Farmanguinhos-Fiocruz, Brazil, against Leishmania (Leishmania) amazonensis, L (L.) chagasi and L (Viannia) braziliensis. Mem Inst Oswaldo Cruz. 2008;103:358-62 pubmed
    The leishmanicidal activity of four batches of meglumine antimoniate, produced in Farmanguinhos-Fiocruz, Brazil (TAMs), was assessed and compared to Glucantime-Aventis Pharma Ltda...
  35. Miranda Verastegui C, Llanos Cuentas A, Arevalo I, Ward B, Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis. 2005;40:1395-403 pubmed
  36. Vouldoukis I, Rougier S, Dugas B, Pino P, Mazier D, Woehrlé F. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate. Vet Parasitol. 2006;135:137-46 pubmed
    ..evaluated in vitro in the presence of Leishmania infantum promastigotes and dog-monocyte-derived macrophages; meglumine antimoniate and sodium stibogluconate were used as comparative treatments...
  37. Moosavi Z, Nakhli A, Rassaii S. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis. Int J Dermatol. 2005;44:1064-5 pubmed
  38. Ribeiro R, Ferreira W, Martins P, Neto R, Rocha O, Le Moyec L, et al. Prolonged absorption of antimony(V) by the oral route from non-inclusion meglumine antimoniate-beta-cyclodextrin conjugates. Biopharm Drug Dispos. 2010;31:109-19 pubmed publisher
    The orally active composition comprising meglumine antimoniate (MA) and beta-cyclodextrin (beta-CD) differs markedly from conventional drug-CD complexes, since it combines a water-soluble drug and a hydrophilic CD...
  39. Michaely H, Kramer H, Dietrich O, Nael K, Lodemann K, Reiser M, et al. Intraindividual comparison of high-spatial-resolution abdominal MR angiography at 1.5 T and 3.0 T: initial experience. Radiology. 2007;244:907-13 pubmed
    ..To prospectively compare three-dimensional (3D) contrast material-enhanced abdominal magnetic resonance (MR) angiography at 1.5 and 3.0 T intraindividually in healthy volunteers...
  40. Lim J, Kim M, Myoung S, Park M, Choi J, Choi J, et al. MR cholangiography for evaluation of hilar branching anatomy in transplantation of the right hepatic lobe from a living donor. AJR Am J Roentgenol. 2008;191:537-45 pubmed publisher
  41. Hwang H, Kim S, Jeon T, Choi D, Lee W, Lim H. Hypointense hepatic lesions depicted on gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy. Korean J Radiol. 2009;10:294-302 pubmed publisher
    ..In contrast, peripheral hypointensity due to rich tumoral cellularity compared to the center with a clear margin may favor an indication of the presence of a malignant hepatic lesion...
  42. Manna L, Reale S, Vitale F, Picillo E, Pavone L, Gravino A. Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol. Vet J. 2008;177:279-82 pubmed
    ..DNA load in different tissues from 18 naturally-infected dogs before and after treatment with a combination of meglumine antimoniate (100mg/kg/day, subcutaneously) and allopurinol (10mg/kg/day, orally) for 30 days...
  43. Arevalo I, Tulliano G, Quispe A, Spaeth G, Matlashewski G, Llanos Cuentas A, et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin Infect Dis. 2007;44:1549-54 pubmed
    ..In the present pilot study, we compared the use of imiquimod, an immunomodulatory molecule, to the use of meglumine antimoniate alone and in combination for the initial treatment of cutaneous leishmaniasis.
  44. Sadeghian G, Nilfroushzadeh M, Iraji F. Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate. Clin Exp Dermatol. 2007;32:371-4 pubmed
    ..Cutaneous leishmaniasis (CL) is a serious public health problem in many tropical and subtropical regions of the world. Treatment of CL can prevent disfiguring scars...
  45. Layegh P, Pezeshkpoor F, Soruri A, Naviafar P, Moghiman T. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children. Am J Trop Med Hyg. 2009;80:172-5 pubmed
    ..Because of its simplicity, lower cost, low rate of serious complications, and greater tolerability, cryotherapy should be recommended as an appropriate alternative treatment for leishmaniasis in children...
  46. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med. 2006;3:e162 pubmed
    ..evidence suggests that an increasing number of Iranian patients with cutaneous leishmaniasis are unresponsive to meglumine antimoniate (Glucantime), the first line of treatment in Iran...
  47. Dzamitika S, Falcão C, de Oliveira F, Marbeuf C, Garnier Suillerot A, Demicheli C, et al. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance. Chem Biol Interact. 2006;160:217-24 pubmed
    ..investigate the role of residual Sb(III) both in the antileishmanial/antitumoral activities of the pentavalent meglumine antimoniate and in the MRP1 (multidrug resistance-associated protein 1)-mediated resistance to this drug...
  48. Mayrink W, Botelho A, Magalhães P, Batista S, Lima A, Genaro O, et al. Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment. Rev Soc Bras Med Trop. 2006;39:14-21 pubmed
    ..9% and treatment length from 87 to 62 days, decreasing side effects...
  49. Kashani M, Firooz A, Eskandari S, Ghoorchi M, Khamesipour A, Khatami A, et al. Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis. Eur J Dermatol. 2007;17:513-5 pubmed
    ..Pentavalent antimonies, meglumine antimoniate and sodium stibogluconate, have been considered as standard treatment for leishmaniasis...
  50. Krolewiecki A, Romero H, Cajal S, Abraham D, Mimori T, Matsumoto T, et al. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. Am J Trop Med Hyg. 2007;77:640-6 pubmed
    Azithromycin was compared with meglumine antimoniate for treatment of patients with cutaneous leishmaniasis...
  51. Tsushima Y, Takahashi Taketomi A, Endo K. Nephrogenic systemic fibrosis in Japan: advisability of keeping the administered dose as low as possible. Radiology. 2008;247:915-6 pubmed publisher
  52. Marin D, Iannaccone R, Catalano C, Passariello R. Multinodular focal fatty infiltration of the liver: atypical imaging findings on delayed T1-weighted Gd-BOPTA-enhanced liver-specific MR images. J Magn Reson Imaging. 2006;24:690-4 pubmed
    ..Because at present there is no report evaluating the kinetics of Gd-BOPTA in fatty liver, further studies are needed to specifically investigate this issue...
  53. Araujo Melo M, Meneses A, Schubach A, Moreira J, Conceição Silva F, Salgueiro M, et al. Risk factors associated with dizziness during treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil. J Laryngol Otol. 2010;124:1056-60 pubmed publisher
    To evaluate dizziness in patients receiving meglumine antimoniate for the treatment of mucosal leishmaniasis.